LIPOSOMAL AGENT FOR TREATING CHRONIC ATROPHIC GASTRITIS Russian patent published in 2020 - IPC A61K35/51 A61K9/127 

FIELD: medicine.

SUBSTANCE: invention relates to medicine and discloses use of agent, which is a liposomal form α-fetoprotein (AFP). Liposomal form of the AFP can be an aqueous suspension of liposomes or a lyophilizate. Aqueous suspension of liposomes contains AFP, lipoid C-100, cholesterol, lactose, rheopolyglucin, alpha-tocopherol (vitamin E), sodium chloride, disubstituted sodium phosphate in aqueous form, aqueous sodium monophosphate, water in the following weight ratio of components: AFP - 0.040–0.160; S-100 lipoid - 41.6–43.8; cholesterol - 4.0–5.3; alpha-tocopherol (vitamin E) - 0.48–0.8; lactose - 70–120; rheopolyglucin - 4.0–6.0; sodium chloride - 7.0–9.0; disubstituted di-sodium phosphate - 4.3–4.9; mono-substituted 2-aqueous sodium phosphate - 0.5–0.7; water - 800–1300. Lyophilizate contains the above components, except water, in the same weight ratio. Average diameter of liposomes is 0.18 mcm. AFP is recovered from human umbilical blood.

EFFECT: invention allows to achieve the same results in recovery of the gastric mucosa within 2 weeks of treatment, which is achieved by the prototype (water-oil form of AFP) for 4 weeks.

9 cl, 12 dwg, 2 tbl, 1 ex